Surgery Partners, Inc. (NASDAQ:SGRY) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On December 19, RBC Capital reiterated its Buy rating on Surgery Partners, Inc. (NASDAQ:SGRY) with a price target of $31 on the stock. The research firm believes that the company’s long-term growth prospects are still intact. Earlier, on December 18, Mizuho Securities reduced its price target on Surgery Partners, Inc. (NASDAQ:SGRY) from $22 to $19 but kept its Outperform rating on the shar ...

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. concerning allegations of securities fraud and unlawful business practices by the company and its officers [2]. Financial Performance - On November 12, 2025, Ardent reported a $43 million decrease in third quarter 2025 revenue due to revised determinations of accounts receivable collectability after transitioning to a new revenue accounting system [3]. - The new accounting system, Kodiak RCA net revenue platform, allows for more precise determination of accounts receivable collectability and recognizes reserves earlier in an account's life cycle compared to the previous framework [3]. - Ardent also cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $625 million to $530 million - $555 million, citing persistent industry-wide cost pressures [3]. - Additionally, the company recorded a $54 million increase in professional liability reserves related to recent settlements and ongoing litigation, influenced by broader industry trends [3]. - Following these announcements, Ardent's stock price fell by $4.75 per share, or 33.81%, closing at $9.30 per share on November 13, 2025 [3].

Core Viewpoint - A securities class action lawsuit has been filed against Ardent Health, Inc. following significant adverse accounting adjustments of approximately $90 million, leading to a stock price decline of over 33% [1] Group 1: Lawsuit Details - The lawsuit seeks to represent investors who acquired Ardent securities between July 18, 2024, and November 12, 2025 [1] - The lead plaintiff deadline for the lawsuit is set for March 9, 2026 [3] - The case is titled Postiwala v. Ardent Health, Inc. et al., No. 3:26-cv-00022 (M.D. Tenn.) [3] Group 2: Allegations and Investigations - Hagens Berman is investigating claims that Ardent's leadership failed to disclose material weaknesses in internal controls related to revenue recognition and liability reserves [2] - The complaint alleges that timely writing off uncollectible accounts is crucial to avoid inflating accounts receivable [4] - The lawsuit claims that Ardent misled investors regarding its reliance on detailed reviews of historical collections for determining accounts receivable collectability [5] Group 3: Financial Disclosures and Market Reaction - On November 12, 2025, Ardent disclosed a $42.6 million decrease in revenue due to changes in accounting estimates and new information from hindsight evaluations [6] - The CFO revealed that the company's collectability framework used a 180-day cliff for reserving accounts, contradicting earlier assurances [6] - Following the disclosures, Ardent's stock price fell by $4.75, a decline of 33% [6] Group 4: Implications and Further Actions - The significant revenue reduction of $43 million and reserve increase of $54 million raises questions about whether these issues should have been disclosed earlier [7] - Investors who suffered losses are encouraged to contact Hagens Berman for potential recovery options [7]

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of agilon health, inc. (NYSE: AGL). Shareholders who purchased shares of AGL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/agilon-health-inc-loss-submission-form/?id=182869&from=3  CLASS PERIOD: February 2 ...

WASHINGTON (AP) — Sluggish December hiring concluded a year of weak employment gains that have frustrated job seekers even though layoffs and unemployment remained low. Employers added just 50,000 jobs last month, nearly unchanged from a downwardly revised figure of 56,000 in November, the Labor Department said Friday. The unemployment rate slipped to 4.4%, its first decline since June, from 4.5% in November, a figure also revised lower. The data suggests a reluctance by businesses to add workers even a ...

Faruqi & Faruqi, LLP also encourages anyone with information regarding Ardent's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Ardent Health (ARDT) To Contact Him Directly To Discuss Their Options If you purchased or acquired Ardent Health securities between July 18, 2024 and November 12, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Forunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- What’s Ha ...

Detroit, Jan. 08, 2026 (GLOBE NEWSWIRE) -- BAMF Health and Henry Ford Health today announced a strategic partnership to establish a Comprehensive Theranostics Center in downtown Detroit at the Life Sciences Building on Bedrock’s Gratiot Site. The joint venture represents a major advancement in expanding patient access to precision medicine and reinforces Detroit’s role as a national destination for innovation. By combining BAMF Health’s global leadership in Theranostics with Henry Ford Health’s century-long ...

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Agilon Health, Inc. for alleged misrepresentations regarding the company's guidance for 2025, affecting investors who purchased securities between February 26, 2025, and August 4, 2025 [1][2]. Group 1 - The lawsuit claims that the defendants made misrepresentations concerning the company's issued guidance for 2025 [2]. - Investors who wish to serve as lead plaintiffs must file papers by March 2, 2026, but participation in any recovery does not require serving as lead plaintiff [3]. - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [4].

Core Insights - ClearBridge Investments released its fourth-quarter 2025 investor letter for the ClearBridge Large Cap Growth Strategy, emphasizing an investment philosophy focused on undervalued leading companies with growth potential [1] - Large-cap stocks showed strength in the quarter, driven by strong earnings from mega-cap companies and enthusiasm for generative AI, although the ClearBridge strategy underperformed the Russell 1000 Growth Index by approximately 900 basis points for the year [1] - The underperformance was attributed to underweight exposure to mega-cap AI beneficiaries and lower-quality AI-related names, with a quarterly lag of about 170 basis points [1] Company-Specific Insights - UnitedHealth Group Incorporated (NYSE:UNH) was highlighted in the investor letter, with a one-month return of 1.48% and a 52-week loss of 34.85%, closing at $341.70 per share on January 7, 2026, with a market capitalization of $309.525 billion [2] - The performance of UnitedHealth was disappointing, with the stock losing about half its value in 2025 due to negative sentiment and mismanagement, leading the company to exit the position in August [3] - Despite a long-term track record of solid returns, the company faced challenges in disclosure and execution issues, ultimately leading to a loss of confidence in its ability to navigate a turnaround under new leadership [3]